These advances suggest that therapeutic efforts to treat FTD-GRN could target the sortilin-PGRN axis to prevent PGRN degradation and thereby elevate its level in the brains of individuals with FTD-GRN. The gene discussed is GRN; the disease is frontotemporal dementia.